NRIX Stock Latest News

Nurix Therapeutics assumed with an Outperform at Oppenheimer

PremiumThe Fly

10d ago

Nurix Therapeutics price target raised to $33 from $26 at Baird

PremiumThe Fly

21d ago

Nurix Maintained at Buy as Bexobrutideg Data Underscore Safety Edge; $34 Price Target Reaffirmed

PremiumRatings

24d ago

Nurix Highlights Promising Phase 1b Data for Bexobrutideg

PremiumCompany Announcements

28d ago

PremiumThe FlyNurix Therapeutics price target raised to $32 from $30 at Truist

30d ago

Nurix Therapeutics price target raised to $32 from $30 at BTIG

The Fly

Nurix Therapeutics price target raised to $32 from $30 at BTIG

1M ago

Morgan Stanley’s Terence Flynn Reiterates Buy on Nurix, Citing Value-Creating Roche Partnership and Long‑Term Bexobrutideg Growth Potential

Ratings

Morgan Stanley’s Terence Flynn Reiterates Buy on Nurix, Citing Value-Creating Roche Partnership and Long‑Term Bexobrutideg Growth Potential

1M ago

Nurix Therapeutics price target raised to $32 from $30 at Truist

PremiumThe Fly

1M ago

Nurix Therapeutics price target raised to $45 from $41 at Jefferies

PremiumThe Fly

1M ago

Nurix Therapeutics price target raised to $34 from $26 at Needham

PremiumThe Fly

1M ago

Nurix Therapeutics downgraded to Equal Weight at Wells Fargo after Roche deal

PremiumThe Fly

1M ago

PremiumThe FlyNurix Therapeutics downgraded to Equal Weight from Overweight at Wells Fargo

1M ago

Video: Marvell, Flex rise after selection for S&P 500

The Fly

Video: Marvell, Flex rise after selection for S&P 500

1M ago

CPB

LLY

Morning Movers: Corning jumps after optical supply deal with Amazon

Nurix and Roche forge global BTK degrader alliance

The Fly

Morning Movers: Corning jumps after optical supply deal with Amazon

1M ago

CPB

GHM

PremiumCompany Announcements

1M ago

Nurix Therapeutics Stock (NRIX) Soars 40% After $2.3B Blood Cancer Deal with Roche

PremiumMarket News

1M ago

Nurix Therapeutics teams with Roche to develop, commercialize bexobrutideg

PremiumThe Fly

1M ago

Nurix Therapeutics Shareholders Back Directors and Governance Proposals

PremiumCompany Announcements

2M ago

PremiumRatingsGil Blum Reiterates Buy on Nurix, Maintains $26 Price Target on Advancing Degrader Pipeline

2M ago

Analyst Reiterates Buy on Nurix, Maintains $32 Price Target on Strength of Degrader Platform and Pipeline

Ratings

Analyst Reiterates Buy on Nurix, Maintains $32 Price Target on Strength of Degrader Platform and Pipeline

2M ago

Ratings

Buy Rating on Nurix Therapeutics Backed by Strong Clinical Momentum, Strategic Execution, and Attractive Risk‑Reward Profile

3M ago